SG11202107720UA - Cnx/erp57 inhibitor for use in the treatment or prevention of cancer - Google Patents
Cnx/erp57 inhibitor for use in the treatment or prevention of cancerInfo
- Publication number
- SG11202107720UA SG11202107720UA SG11202107720UA SG11202107720UA SG11202107720UA SG 11202107720U A SG11202107720U A SG 11202107720UA SG 11202107720U A SG11202107720U A SG 11202107720UA SG 11202107720U A SG11202107720U A SG 11202107720UA SG 11202107720U A SG11202107720U A SG 11202107720UA
- Authority
- SG
- Singapore
- Prior art keywords
- cnx
- cancer
- prevention
- treatment
- erp57
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4727—Calcium binding proteins, e.g. calmodulin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/99—Isomerases (5.)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG10201900943X | 2019-01-31 | ||
PCT/SG2020/050044 WO2020159445A1 (en) | 2019-01-31 | 2020-01-30 | Cnx/erp57 inhibitor for use in the treatment or prevention of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202107720UA true SG11202107720UA (en) | 2021-08-30 |
Family
ID=71842463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202107720UA SG11202107720UA (en) | 2019-01-31 | 2020-01-30 | Cnx/erp57 inhibitor for use in the treatment or prevention of cancer |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP3917571A4 (en) |
CN (1) | CN113365661A (en) |
SG (1) | SG11202107720UA (en) |
WO (1) | WO2020159445A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114106188B (en) * | 2021-12-30 | 2022-07-19 | 深圳市人民医院 | Nano antibody targeting disulfide isomerase A3 and application thereof |
WO2024008960A1 (en) | 2022-07-08 | 2024-01-11 | Agency For Science, Technology And Research | Cnx antigen-binding molecules |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
US4631211A (en) | 1985-03-25 | 1986-12-23 | Scripps Clinic & Research Foundation | Means for sequential solid phase organic synthesis and methods using the same |
SU1441787A1 (en) | 1987-04-29 | 1990-09-23 | Институт Белка Ан Ссср | Method of producing peptides and proteins in cell-less translation system |
AU649217B2 (en) | 1988-11-18 | 1994-05-19 | Regents Of The University Of California, The | Method for site-specifically incorporating unnatural amino acids into proteins |
SU1705302A1 (en) | 1988-12-22 | 1992-01-15 | Институт Белка Ан Ссср | Method of preparative genes expression in the cell-free system of coupled transcription/translation |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
CA2064754C (en) | 1989-07-31 | 1996-06-18 | Vladimir Ivanovich Baranov | Method of preparing polypeptides in a cell-free translation system |
KR0185192B1 (en) | 1989-10-05 | 1999-04-01 | 제임스 더블유. 데이비 | Cell-free synthesis and isolation of novel genes and polypeptides |
US5650489A (en) | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
AU8498091A (en) | 1990-08-02 | 1992-03-02 | Regents Of The University Of Colorado, The | Systematic polypeptide evolution by reverse translation |
WO1992005258A1 (en) | 1990-09-20 | 1992-04-02 | La Trobe University | Gene encoding barley enzyme |
ES2155822T3 (en) | 1990-12-06 | 2001-06-01 | Affymetrix Inc | COMPOUNDS AND ITS USE IN A BINARY SYNTHESIS STRATEGY. |
JPH06508022A (en) | 1991-02-21 | 1994-09-14 | ギリアド サイエンシズ,インコーポレイテッド | Biomolecule-specific aptamers and production methods |
JP2001524926A (en) | 1991-09-18 | 2001-12-04 | アフィマックス テクノロジーズ ナームロゼ フェンノートシャップ | Method for synthesizing a heterogeneous library of oligomers |
WO1995011922A1 (en) | 1993-10-29 | 1995-05-04 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
GB9416721D0 (en) | 1994-08-18 | 1994-10-12 | Short Brothers Plc | A bias yarn assembly forming device |
USRE45795E1 (en) | 1994-08-20 | 2015-11-10 | Gendaq, Ltd. | Binding proteins for recognition of DNA |
ES2176484T3 (en) | 1995-08-18 | 2002-12-01 | Morphosys Ag | PROTEIN BANKS / (POLI) PEPTIDES. |
GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
US6083682A (en) | 1997-12-19 | 2000-07-04 | Glaxo Group Limited | System and method for solid-phase parallel synthesis of a combinatorial collection of compounds |
AU751487B2 (en) | 1998-03-17 | 2002-08-15 | Gendaq Limited | Nucleic acid binding proteins |
EP1230355A2 (en) | 1999-10-01 | 2002-08-14 | Sangamo Biosciences Inc. | Dna library and its use in methods of selecting and designing polypeptides |
EP2320235A1 (en) * | 2009-11-06 | 2011-05-11 | IMG Institut für medizinische Genomforschung Planungsgesellschaft M.B.H. | Marker for prostate cancer diagnosis |
WO2013011153A2 (en) * | 2011-07-21 | 2013-01-24 | Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) | Method for the prognosis and treatment of metastasis in breast cancer |
CN108277275B (en) * | 2017-01-03 | 2021-11-09 | 中山大学附属口腔医院 | Use of calnexin in screening of drugs for diagnosis or treatment of tumor-related diseases |
US11740242B2 (en) * | 2017-07-14 | 2023-08-29 | Dana-Farber Cancer Institute, Inc. | Modulating biomarkers to increase tumor immunity and improve the efficacy of cancer immunotherapy |
EP3692371A4 (en) * | 2017-10-04 | 2021-06-09 | Agency for Science, Technology and Research | Biomarkers to detect and characterise cancer |
CN108309988B (en) * | 2018-05-04 | 2020-05-26 | 遵义医学院 | ERp57 inhibitor compound and application |
-
2020
- 2020-01-30 SG SG11202107720UA patent/SG11202107720UA/en unknown
- 2020-01-30 WO PCT/SG2020/050044 patent/WO2020159445A1/en unknown
- 2020-01-30 CN CN202080012262.3A patent/CN113365661A/en active Pending
- 2020-01-30 EP EP20747649.0A patent/EP3917571A4/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN113365661A (en) | 2021-09-07 |
EP3917571A1 (en) | 2021-12-08 |
WO2020159445A1 (en) | 2020-08-06 |
EP3917571A4 (en) | 2022-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL3672639T3 (en) | Combination product of a bcl-2 inhibitor and ibrutinib for use in the prevention and/or treatment of cancer | |
IL272948B1 (en) | Enpp1 inhibitors and their use for the treatment of cancer | |
IL255189B2 (en) | A combination of rad1901 and a cdk4/6 inhibitor for use in treating cancer | |
IL279347A (en) | Gremlin-1 antagonist for the prevention and treatment of cancer | |
HK1259545A1 (en) | Combination of bcl-2 inhibitor and mek inhibitor for the treatment of cancer | |
IL290011A (en) | Ezh2 inhibition in combination therapies for the treatment of cancers | |
EP4081527A4 (en) | The combination of cyclin dependent kinase 7 inhibitor and immunotherapy for treatment of cancer | |
IL281999A (en) | Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer | |
IL290415A (en) | Deuterated compounds for use in the treatment of cancer | |
EP3888648A4 (en) | Treatment of cancer by combination of immune checkpoint inhibitor and folfirinox therapy | |
SG11202107720UA (en) | Cnx/erp57 inhibitor for use in the treatment or prevention of cancer | |
IL288522A (en) | Egfr inhibitor for the treatment of cancer | |
IL276668A (en) | Thioredoxin reductase inhibitors for use in the treatment of cancer | |
ZA202007955B (en) | Ccr5 inhibitor for use in treating cancer | |
IL276905A (en) | Treatment and prevention of pre-eclampsia | |
ZA202202617B (en) | Treatment of cancer using a combination comprising multi-tyrosine kinase inhibitor and immune checkpoint inhibitor | |
IL290656A (en) | Lurbinectedin in the treatment of malignant mesothelioma | |
IL287050A (en) | Compounds for the treatment of oncovirus induced cancer and methods of use thereof | |
IL284124A (en) | Quinoline derivatives for use in the treatment or prevention of cancer | |
IL270306A (en) | Prevention and treatment of pre-myeloid and myeloid malignancies | |
IL268860A (en) | Granzyme b inhibitor compositions and methods for the prevention and/or treatment of skin blistering and/or peeling | |
EP3987032A4 (en) | Methods and compositions for the treatment of cancer | |
HUP1900281A1 (en) | Use of monoamine-oxidase-b inhibitors in the prevention or treatment of prostate cancer | |
GB201815694D0 (en) | Prevention and treatment of cancer | |
GB201809946D0 (en) | Prevention and treatment of cancer |